MORRISVILLE, N.C., February 17, 2021 – Myocardial Solutions,Inc. (“MSI”) will attend the Society for Cardiovascular Magnetic Resonance’s (“SCMR”) 24th annual scientific sessions virtually from February 18-21, 2021. The event focuses on highlighting breakthrough developments in new cardiovascular magnetic resonance (CMR) techniques, bringing together leading experts and industry figures from around the world to share new research and clinical validations for the use of CMR in cardiovascular medicine. Additionally, following the COVID pandemic in 2020, this year’s SCMR will also explore CMR’s role for assessing the cardiac effects of COVID-19 on patients.
MyoStrain is set to be featured in two new abstract posters, as well as a presentation by MSI’s Chief Medical Officer Rafael Rivero, MD. The presentation, titled “Transforming the Cancer & Cardiac Care Continuum.Early & Accurate Identification of Patients at Risk of Heart Failure,” will be held as part of the Philips Healthcare User Meeting where Dr. Rivero will share new clinical data on MyoStrain as an additional tool to help guide early risk assessment and cardiac management for asymptomatic heart failure patients.
List of the abstracts to be presented are provided below:
Abstract: Steen, H et al. Fast-Strain Encoded during Adenosine Stress Cardiac Magnetic Resonance for the Assessment of Cardiac Outcomes. Comparison to Contrast-Enhanced Perfusion Testing. Abstract at SCMR 2021.
Abstract: Lee, M et al. Evidence of Occult Myocardial Abnormalities Including Myocardial Strain in the Absence of Myocarditis in Asymptomatic Young Athletes after COVID-19 Infection. Abstract at SCMR 2021.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.